These data were confirmed by the European multicenter study analysing HAv anti-β2GPI that enrolled 226 out of 479 patients with primary APS and APS associated with other autoimmune diseases as well as patients with other non-APS autoimmune diseases [14]. The gene discussed is APOH; the disease is autoimmune polyendocrinopathy.